News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
576,091 Results
Type
Article (41714)
Company Profile (68)
Press Release (534303)
Multimedia
Podcasts (89)
Webinars (19)
Section
Business (175033)
Career Advice (2463)
Deals (27923)
Drug Delivery (127)
Drug Development (73431)
Employer Resources (141)
FDA (13988)
Job Trends (12313)
News (272808)
Policy (27161)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2581)
Academic (1)
Accelerated approval (53)
ADA (49)
Adcomms (35)
Allergies (188)
Alliances (38438)
ALS (223)
Alzheimer's disease (1865)
Antibody-drug conjugate (ADC) (512)
Approvals (14422)
Artificial intelligence (682)
ASCO (345)
Autoimmune disease (327)
Automation (55)
Bankruptcy (313)
Best Places to Work (9995)
BIO (62)
BIOSECURE Act (16)
Biosimilars (218)
Biotechnology (56)
Bladder cancer (203)
Brain cancer (71)
Breast cancer (769)
Cancer (6072)
Cardiovascular disease (508)
Career advice (2099)
Career pathing (45)
CAR-T (334)
CDC (58)
Celiac Disease (1)
Cell therapy (906)
Cervical cancer (48)
Clinical research (64887)
Collaboration (1906)
Commercialization (1)
Company closure (6)
Compensation (772)
Complete response letters (96)
COVID-19 (2620)
CRISPR (104)
C-suite (1292)
Cystic fibrosis (133)
Data (8396)
Decentralized trials (3)
Denatured (14)
Depression (187)
Dermatology (96)
Diabetes (648)
Diagnostics (6349)
Digital health (52)
Diversity (9)
Diversity, equity & inclusion (39)
Drug discovery (308)
Drug pricing (187)
Drug shortages (27)
Duchenne muscular dystrophy (310)
Earnings (59607)
Editorial (67)
Employer branding (18)
Employer resources (136)
Events (81140)
Executive appointments (1142)
FDA (17749)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (21)
Frontotemporal dementia (34)
Funding (1620)
Gene editing (232)
Generative AI (60)
Gene therapy (753)
GLP-1 (1079)
Government (4450)
Grass and pollen (7)
Guidances (417)
Healthcare (16180)
Hematology (168)
HIV (85)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (114)
Immunology and inflammation (321)
Immuno-oncology (103)
Indications (203)
Infectious disease (2972)
Inflammatory bowel disease (212)
Inflation Reduction Act (13)
Influenza (134)
Intellectual property (297)
Interviews (532)
IPO (12655)
IRA (49)
Job creations (2591)
Job search strategy (1678)
JPM (56)
Kidney cancer (23)
Labor market (79)
Layoffs (533)
Leadership (49)
Legal (5784)
Liver cancer (101)
Longevity (27)
Lung cancer (840)
Lymphoma (456)
Machine learning (55)
Management (53)
Manufacturing (993)
Marketing (5)
MASH (230)
Medical affairs (1)
Medical device (11092)
Medtech (11239)
Mergers & acquisitions (16447)
Metabolic disorders (1639)
mRNA (212)
Multiple sclerosis (197)
NASH (24)
Neurodegenerative disease (473)
Neuropsychiatric disorders (119)
Neuroscience (3495)
Neurotech (1)
NextGen: Class of 2026 (5538)
Non-profit (4030)
Now hiring (71)
Obesity (738)
Opinion (306)
Ovarian cancer (235)
Pain (257)
Pancreatic cancer (344)
Parkinson's disease (383)
Partnered (30)
Patents (603)
Patient recruitment (759)
Peanut (60)
People (53412)
Pharmaceutical (14)
Pharmacy benefit managers (20)
Phase 1 (19967)
Phase 2 (28542)
Phase 3 (21766)
Pipeline (9553)
Policy (315)
Postmarket research (2320)
Preclinical (8172)
Press Release (54)
Prostate cancer (322)
Psychedelics (68)
Radiopharmaceuticals (301)
Rare diseases (1160)
Real estate (4147)
Recruiting (61)
Regulatory (22473)
Reports (33)
Research institute (2198)
Resumes & cover letters (360)
Rett syndrome (44)
RNA editing (25)
RSV (79)
Schizophrenia (187)
Series A (278)
Series B (204)
Service/supplier (2)
Sickle cell disease (119)
Special edition (22)
Spinal muscular atrophy (169)
Sponsored (44)
Startups (2803)
State (2)
Stomach cancer (19)
Supply chain (112)
Tariffs (75)
The Weekly (73)
Vaccines (1069)
Venture capital (115)
Weight loss (487)
Women's health (110)
Worklife (21)
Date
Today (33)
Last 7 days (379)
Last 30 days (1676)
Last 365 days (26713)
2026 (14789)
2025 (26488)
2024 (30529)
2023 (34090)
2022 (44520)
2021 (47760)
2020 (46277)
2019 (39622)
2018 (30027)
2017 (26938)
2016 (25607)
2015 (29973)
2014 (22438)
2013 (18234)
2012 (19467)
2011 (20494)
2010 (18083)
Location
Africa (737)
Alabama (85)
Alaska (4)
Arizona (260)
Arkansas (12)
Asia (35590)
Australia (7393)
California (11648)
Canada (3631)
China (1414)
Colorado (501)
Connecticut (495)
Delaware (395)
Europe (80160)
Florida (1915)
Georgia (374)
Hawaii (1)
Idaho (54)
Illinois (1008)
India (92)
Indiana (555)
Iowa (20)
Japan (555)
Kansas (122)
Kentucky (41)
Louisiana (54)
Maine (62)
Maryland (1465)
Massachusetts (8120)
Michigan (326)
Minnesota (580)
Mississippi (5)
Missouri (140)
Montana (26)
Nebraska (26)
Nevada (137)
New Hampshire (79)
New Jersey (3322)
New Mexico (23)
New York (3168)
North Carolina (1435)
North Dakota (7)
Northern California (5806)
Ohio (343)
Oklahoma (13)
Oregon (30)
Pennsylvania (2391)
Puerto Rico (28)
Rhode Island (40)
South America (999)
South Carolina (81)
South Dakota (2)
Southern California (4747)
Tennessee (193)
Texas (2002)
United States (41761)
Utah (388)
Vermont (2)
Virginia (301)
Washington D.C. (65)
Washington State (977)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
576,091 Results for "medrobotics formerly known as cardiorobotics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers
July 8, 2026
·
5 min read
Press Releases
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
June 16, 2026
·
6 min read
Press Releases
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
March 30, 2026
·
19 min read
Press Releases
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis
May 17, 2026
·
3 min read
Press Releases
BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines
February 25, 2026
·
4 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
March 25, 2026
·
2 min read
Press Releases
Jaguar Gene Therapy Announces Successful Completion of Dosing of First Patient Cohort in Clinical Trial Evaluating JAG201 for the Treatment of a Leading Monogenic Cause of Autism Spectrum Disorder Known as Phelan-McDermid Syndrome
February 24, 2026
·
11 min read
Press Releases
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
March 15, 2026
·
10 min read
1 of 57,610
Next
